Literature DB >> 15380277

Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.

Daniel J Wolter1, Ellen Smith-Moland, Richard V Goering, Nancy D Hanson, Philip D Lister.   

Abstract

Fluoroquinolones and carbapenems are important drug classes used for the treatment of Pseudomonas aeruginosa infections. However, overexpression of the P. aeruginosa efflux pump, MexEF-OprN, can provide dual resistance to both fluoroquinolones and carbapenems. Recently, a hospital in Texas encountered several P. aeruginosa isolates resistant to both of these drug classes. The purpose of this study was to determine whether the mechanism responsible for this multidrug resistance involved the overexpression of MexEF-OprN. To test this hypothesis, 7 clinical isolates from the Texas hospital were analyzed for clonality, antimicrobial susceptibility, expression of the porin, oprD, and four multidrug-resistant efflux pumps (mexAB-oprM, mexCD-oprJ, mexEF-oprN, and mexXY), quinolone resistance-determining region mutations, and beta-lactamase production. Two groups of isolates possessed similar pulse field gel electrophoresis patterns indicating their genetic relatedness. In addition to fluoroquinolone and carbapenem resistance, each isolate also displayed varying degrees of susceptibility to additional beta-lactams tested and resistance to gentamicin. Interestingly, none of the 7 clinical isolates overexpressed mexEF-oprN as determined by semiquantitative reverse transcriptase polymerase chain reaction, but overexpression of mexXY was observed in 6 of the 7 isolates. All 7 isolates showed a decrease of OprD in the outer membrane and a reduction in transcriptional expression of oprD compared to wild-type strain, PAO1. These results demonstrate that multidrug resistance to the fluoroquinolones and carbapenems in these clinical isolates was not a result of the overexpression of the mexEF-oprN pump. Instead, resistance to these two agents seemed to arise through independent mutational events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380277     DOI: 10.1016/j.diagmicrobio.2004.05.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  19 in total

1.  AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 2.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.

Authors:  Daniel J Wolter; Amber J Schmidtke; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 4.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

5.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.

Authors:  Alain A Ocampo-Sosa; Gabriel Cabot; Cristina Rodríguez; Elena Roman; Fe Tubau; María D Macia; Bartolomé Moya; Laura Zamorano; Cristina Suárez; Carmen Peña; María A Domínguez; Gabriel Moncalián; Antonio Oliver; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

7.  Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Authors:  Zoya Hojabri; Mohammad Ahangarzadeh Rezaee; Mohammad Reza Nahaei; Mohammad Hossein Soroush; Morteza Ghojazadeh; Tahereh Pirzadeh; Mostafa Davodi; Mona Ghazi; Reza Bigverdi; Omid Pajand; Mohammad Aghazadeh
Journal:  Adv Pharm Bull       Date:  2013-02-07

8.  Kinetic Control of Quorum Sensing in Pseudomonas aeruginosa by Multidrug Efflux Pumps.

Authors:  David Wolloscheck; Ganesh Krishnamoorthy; Jennifer Nguyen; Helen I Zgurskaya
Journal:  ACS Infect Dis       Date:  2017-11-10       Impact factor: 5.084

9.  The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa.

Authors:  S A Dunham; C J McPherson; A A Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-23       Impact factor: 3.267

Review 10.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.